Health Plan Best Practices for the Evolving Management of Atopic Dermatitis Infographic

  • Release Date: December 14, 2022
  • Expiration Date: June 30, 2024
  • Estimated Time to Complete Activity: 0.5 hour
  • Compatible with all modern browsers and mobile devices
Planning Committee Chairs:

Peter Lio, MD, FAAD
Northwestern University Feinberg School of Medicine
Chicago Integrative Eczema Center
Click here for biography

Dana McCormick, RPh, FAMCP
Director of Pharmacy
Blue Cross Blue Shield of Texas
Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
An action plan to enhance knowledge of clinical, economic, and humanistic burden of AD is needed by managed care and payer decision makers to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes. These health care professionals also need increased knowledge of recently approved and emerging AD therapies in order to develop and implement AD benefit design strategies that support an improvement in overall patient quality of life and clinical outcomes. This includes knowledge of the heterogeneity of the presentation of AD and the need to align specific therapies with specific patient types. Furthermore, it is clear that payers can benefit from dermatology providers’ experience and expertise when creating PA criteria in order to streamline utilization controls in order to improve patient access to appropriate therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Eczema Association (NEA), and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this enduring activity for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.5 contact hours.

Pharmacy Education
Medical Education Resources (MER) designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0003680-9999-22-043-H01-P
This activity is certified as Knowledge-based CPE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty

Reported Financial Relationship

Peter Lio, MD, FAAD Grant/Research Support: AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Speakers Bureau/Honoraria for non-CME: Regeneron/Sanofi Genzyme, Pfizer, AbbVie, Eli Lilly, LEO, Galderma, Incyte, and L'Oreal
Consultant/Advisory Board: Almirall, ASLAN Pharmaceuticals, Concerto Biosciences, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharmaceuticals, Dermira, AbbVie, Eli Lilly, Micreos, Lipidor, L'Oreal, Pierre-Fabre, Johnson & Johnson, Janssen, Castle Biosciences, Level Ex, Boston Skin Science (KPAway), Unilever, Menlo Therapeutics, Theraplex, Kaleido Biosciences, IntraDerm, AOBiome, Lipidor, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, YobeeCare, Burt's Bees, SkinFix, Sibel Health, Sonica LLC, My-Or Diagnostics, and Kimberly-Clark.
Dana McCormick, RPh, FAMCP Dana McCormick, RPh, FAMCP has nothing to disclose

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager

Reported Financial Relationship

MER Content Managers No financial relationships to disclose.
NEA Content Managers No financial relationships to disclose.
Impact Education, LLC Staff No financial relationships to disclose.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, the National Eczema Association (NEA), and Impact Education, LLC, and/or, Sanofi and Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

There are no fees for participating and receiving CME/CE credit for this activity. During the period December 14, 2022, through June 30, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.


There is no fee for this educational activity.